Topical atropine for childhood myopia control

• Verfasst von: Li, Yong [VerfasserIn]
• Verfasst von: Yip, Michelle [VerfasserIn]
• Verfasst von: Ning, Yilin [VerfasserIn]
• Verfasst von: Chung, Joey [VerfasserIn]
• Verfasst von: Toh, Angeline [VerfasserIn]
• Verfasst von: Leow, Cheryl [VerfasserIn]
• Verfasst von: Liu, Nan [VerfasserIn]
• Verfasst von: Ting, Daniel [VerfasserIn]
• Verfasst von: Schmetterer, Leopold [VerfasserIn]
• Verfasst von: Saw, Seang-Mei [VerfasserIn]
• Verfasst von: Jonas, Jost B. [VerfasserIn]
• Verfasst von: Chia, Audrey [VerfasserIn]
• Verfasst von: Ang, Marcus [VerfasserIn]
• Titel: Topical atropine for childhood myopia control
• Titelzusatz: The Atropine Treatment Long-Term Assessment Study
• Verf.angabe: Yong Li, Michelle Yip, Yilin Ning, Joey Chung, Angeline Toh, Cheryl Leow, Nan Liu, Daniel Ting, Leopold Schmetterer, Seang-Mei Saw, Jost B. Jonas, Audrey Chia, Marcus Ang
• E-Jahr: 2024
• Jahr: January 2024
• Umfang: 9 S.
• Fussnoten: Online veröffentlicht: 30. November 2023 ; Gesehen am 07.10.2024
• Titel Quelle: Enthalten in: JAMA ophthalmology
• Ort Quelle: Chicago, Ill. : American Medical Association, 2013
• Jahr Quelle: 2024
• Band/Heft Quelle: 142(2024), 1 vom: Jan., Seite 15-23
• ISSN Quelle: 2168-6173
• DOI: doi:10.1001/jamaophthalmol.2023.5467
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1904986706

Abstract

Clinical trial results of topical atropine eye drops for childhood myopia control have shown inconsistent outcomes across short-term studies, with little long-term safety or other outcomes reported.To report the long-term safety and outcomes of topical atropine for childhood myopia control.This prospective, double-masked observational study of the Atropine for the Treatment of Myopia (ATOM) 1 and ATOM2 randomized clinical trials took place at 2 single centers and included adults reviewed in 2021 through 2022 from the ATOM1 study (atropine 1% vs placebo; 1999 through 2003) and the ATOM2 study (atropine 0.01% vs 0.1% vs 0.5%; 2006 through 2012).Change in cycloplegic spherical equivalent (SE) with axial length (AL); incidence of ocular complications.Among the original 400 participants in each original cohort, the study team evaluated 71 of 400 ATOM1 adult participants (17.8% of original cohort; study age, mean [SD] 30.5 [1.2] years; 40.6% female) and 158 of 400 ATOM2 adult participants (39.5% of original cohort; study age, mean [SD], 24.5 [1.5] years; 42.9% female) whose baseline characteristics (SE and AL) were representative of the original cohort. In this study, evaluating ATOM1 participants, the mean (SD) SE and AL were −5.20 (2.46) diopters (D), 25.87 (1.23) mm and -6.00 (1.63) D, 25.90 (1.21) mm in the 1% atropine-treated and placebo groups, respectively (difference of SE, 0.80 D; 95% CI, −0.25 to 1.85 D; P = .13; difference of AL, −0.03 mm; 95% CI, −0.65 to 0.58 mm; P = .92). In ATOM2 participants, the mean (SD) SE and AL was −6.40 (2.21) D; 26.25 (1.34) mm; −6.81 (1.92) D, 26.28 (0.99) mm; and −7.19 (2.87) D, 26.31 (1.31) mm in the 0.01%, 0.1%, and 0.5% atropine groups, respectively. There was no difference in the 20-year incidence of cataract/lens opacities, myopic macular degeneration, or parapapillary atrophy (β/γ zone) comparing the 1% atropine-treated group vs the placebo group.Among approximately one-quarter of the original participants, use of short-term topical atropine eye drops ranging from 0.01% to 1.0% for a duration of 2 to 4 years during childhood was not associated with differences in final refractive errors 10 to 20 years after treatment. There was no increased incidence of treatment or myopia-related ocular complications in the 1% atropine-treated group vs the placebo group. These findings may affect the design of future clinical trials, as further studies are required to investigate the duration and concentration of atropine for childhood myopia control.